# Q8, Q9, & Q10 Questions and Answers -- Appendix:  Q&As from Training Sessions (Q8, Q9, & Q10 Points to Consider) - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/q8-q9-q10-questions-and-answers-appendix-qas-from-training-sessions-q8-q9-q10-points-to-consider/74f08aab-1b94-4f9f-8da0-2725af03d078

> FDA guidance document: Q8, Q9, & Q10 Questions and Answers -- Appendix:  Q&As from Training Sessions (Q8, Q9, & Q10 Points to Consider). Issue date: August 13, 2012. Get complete insights and analysis.

---

## Details

- Title: Q8, Q9, & Q10 Questions and Answers -- Appendix:  Q&As from Training Sessions (Q8, Q9, & Q10 Points to Consider)
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2012-08-13
- Last Changed: 2020-04-15

## Related Documents

- [S6(R1) Addendum: Preclinical Safety Evaluation of Biotechnology:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/s6r1-addendum-preclinical-safety-evaluation-of-biotechnology-guidance-for-industry/23ee2aae-70be-4e30-bfcb-a4cf7a016b71)
- [Q11 Development and Manufacture of Drug Substances](https://www.globalkeysolutions.net/guidances/guidance-document/q11-development-and-manufacture-of-drug-substances/8d1aacb1-7da4-42f7-9a3a-18b2fc871411)
- [Q8, Q9, and Q10 Questions and Answers](https://www.globalkeysolutions.net/guidances/guidance-document/q8-q9-and-q10-questions-and-answers/143dddaa-3858-4f11-a750-8ff7806e5dcd)